deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT05687253

Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery

A Phase 2, Randomized, Double-Blind, Active-Controlled, Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery

Sponsor: Baudax Bio

Conditions Anesthesia Neuromuscular Blockade Surgery
Interventions BX1000 Rocuronium Bromide
Updated 4 times since 2023 Last updated: Jul 28, 2023 Started: Oct 25, 2022 Primary completion: Apr 10, 2023 Completion: May 8, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Anesthesia and Neuromuscular Blockade and is currently completed. Baudax Bio leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Feb 2023 – ~Sep 2023 · 7 months · monthly snapshotRecruiting~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  4. Feb 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Baudax Bio
Data source: Baudax Bio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations